Showing results (31-40 of 40) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 31, 2007
Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trialLaetitia Fartoux, Françoise Degos, Christian Trépo, et al.Gastroenterology|June 14, 2019
Hepatocellular Carcinomas With Mutational Activation of Beta-Catenin Require Choline and Can Be Detected by Positron Emission TomographyAngélique Gougelet, Chiara Sartor, Nadia Senni, et al.Hepatology (Baltimore, Md.)|December 17, 2016
Growth factor receptor binding protein 14 inhibition triggers insulin-induced mouse hepatocyte proliferation and is associated with hepatocellular carcinomaLucille Morzyglod, Michèle Caüzac, Lucie Popineau, et al.European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|November 14, 2019
Preoperative risk score for prediction of long-term outcomes after hepatectomy for intrahepatic cholangiocarcinoma: Report of a collaborative, international-based, external validation studyRaffaele Brustia, Serena Langella, Takayuki Kawai, et al.The Lancet. Oncology|June 8, 2018
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trialAndrew X Zhu, Richard S Finn, Julien Edeline, et al.European Journal of Cancer (Oxford, England : 1990)|April 1, 2022
Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenibMasatoshi Kudo, Richard S Finn, Julien Edeline, et al.Alimentary Pharmacology & Therapeutics|December 21, 2018
LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosisThierry Poynard, Valentina Peta, Olivier Deckmyn, et al.The Lancet. Oncology|May 24, 2014
Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trialDavid Malka, Pascale Cervera, Stéphanie Foulon, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2019
Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III StudyJulien Edeline, Meher Benabdelghani, Aurélie Bertaut, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 28, 2013
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS studyJosep M Llovet, Thomas Decaens, Jean-Luc Raoul, et al.Pageof 4